Adaptimmune Therapeutics plc (ADAP)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 1.0600 |
| Open | 1.0600 |
| Bid | 1.0500 x 1200 |
| Ask | 1.0900 x 600 |
| Day's range | 1.0300 - 1.0901 |
| 52-week range | 0.4200 - 2.0500 |
| Volume | |
| Avg. volume | 2,054,151 |
| Market cap | 274.729M |
| Beta (5Y monthly) | 2.38 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Adaptimmune (ADAP) Down on End of Collaboration With Roche
Adaptimmune's (ADAP) shares plummet as the company;s collaboration to develop and commercialize allogeneic cell therapies with Roche gets terminated.
- Simply Wall St.
Adaptimmune Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
Adaptimmune Therapeutics ( NASDAQ:ADAP ) Full Year 2023 Results Key Financial Results Revenue: US$60.3m (up 122% from...
- GuruFocus.com
Adaptimmune Therapeutics PLC Reports Q4 and Full Year 2023 Financial Results
Key Financial Highlights and Business Updates
© 2024 Yahoo. All rights reserved.